Alopecia areata is a chronic immune-mediated autoimmune disorder targeting hair follicles and causing sudden, nonscarring patchy hair loss. The condition often follows a relapsing course, though spontaneous regrowth can occur.
AbbVie posted record 2025 revenue of $61.2 billion and raised 2026 guidance on Skyrizi and Rinvoq growth. Pipeline advances include Crohn's submissions, obesity data, and European approval for Boey.
AbbVie raised 2026 revenue and EPS guidance after first-quarter results beat estimates, with Skyrizi and Rinvoq driving growth. Humira erosion continued as neuroscience, oncology and pipeline assets supported the outlook.
AbbVie posted record full-year 2025 revenue of $61.2B and raised its 2026 outlook after strong Q1 Skyrizi and Rinvoq sales. Phase 3 AFFIRM data and new FDA submissions highlight pipeline progress, while full-year revenue guidance was lifted to $67.3B.
Nektar said extended rezpeg treatment promoted greater hair growth in severe alopecia areata and reported durable 52-week efficacy for rezpegaldesleukin in atopic dermatitis. The company said it has FDA alignment on Phase 3 design and is targeting a BLA submission by 2029.
AbbVie said Skyrizi and Rinvoq generated $26.0 billion in 2025 sales and are expected to exceed $31 billion in 2026. The company said the two immunology drugs continue to offset Humira erosion and drive top-line growth.
HCW Biologics regained compliance with Nasdaq listing rules and completed a follow-on offering priced at $0.6055 per unit to raise approximately $1.5 million for clinical development of immunotherapies targeting chronic inflammation.
Nektar Therapeutics is advancing its immunology pipeline with plans to initiate Phase 3 trials for REZPEG in atopic dermatitis next quarter, following positive Phase 2b results. The company recently completed a large equity raise to support its regulatory T cell-focused programs.
Recent studies examine safety profiles of GLP-1 receptor agonists, finding increased risk for nonscarring hair loss but improved survival in patients with brain metastases and type 2 diabetes.
The alopecia areata treatment market is projected to grow significantly through 2036, driven by rising prevalence and the anticipated launch of emerging therapies including JAK inhibitors and novel drug classes targeting immune pathways.
Nektar Therapeutics completed a $460 million public offering on February 13, 2026, selling 7.6 million shares of common stock and pre-funded warrants. The clinical-stage biotechnology company is developing immunotherapy treatments for autoimmune diseases.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07762443 |
A Phase I Study of VC005 Tablets in Adolescent Subjects With Severe Alopecia Areata |
NOT_YET_RECRUITING | PHASE1 |
| NCT07757867 |
Microneedling-Assisted Delivery of Cetirizine Versus Latanoprost in Alopecia Areata |
COMPLETED | NA |
| NCT07749716 |
Phase II Clinical Study of VC005 Tablets in Subjects With Severe Alopecia Areata |
NOT_YET_RECRUITING | PHASE2 |
| NCT07748169 |
An Observational Study of Patients With Dermatologic Disease |
RECRUITING | |
| NCT07733765 |
A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areata |
RECRUITING | PHASE3 |
| NCT07733063 |
Serum Ferroptosis Biomarkers (GPX4, MDA) in Alopecia Areata |
RECRUITING | |
| NCT07705217 |
The Role of Gut and Skin Microbiota in Alopecia Areata |
NOT_YET_RECRUITING | NA |
| NCT07696585 |
New Topical Treatment in Patchy Alopecia Areata |
NOT_YET_RECRUITING | NA |
| NCT07645430 |
Assessment of Interleukin-15 and Interferon Gamma in Alopecia Areata Before and After Baricitinib. |
COMPLETED | NA |
| NCT07617597 |
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Japanese Adults With Severe Alopecia Areata |
RECRUITING | PHASE3 |
